Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT.
馬薩諸塞州沃爾瑟姆，2024年11月12日（環球新聞社）- Apellis Pharmaceuticals，Inc.（納斯達克：APLS）宣佈本公司將於2024年11月19日週二上午8:30在倫敦傑弗里斯醫療保健大會上舉行網絡交流。
The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event.
現場會議網絡直播將發佈在公司網站「投資者和媒體」部門的「事件和演示」頁面上。網絡直播重播將在活動結束後約90天內提供。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.
關於Apellis
Apellis Pharmaceuticals是一家全球生物製藥公司，結合勇敢的科學和同情心，爲一些最具挑戰性的疾病患者開發改變生命的治療方案。我們推出了15年來第一個新的補體藥物系，現有兩種針對C3的批准藥物，其中包括全球首款用於地理萎縮症的治療。我們相信，我們才剛剛開始釋放針對C3治療嚴重眼部、罕見和神經系統疾病的潛力。欲了解更多信息，請訪問或關注我們的Twitter和LinkedIn。
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投資者聯繫：
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
譯文內容由第三人軟體翻譯。
